nach oben

Digestive Diseases and Sciences

Erschienen in:

01.03.2009 | Review

On the Use of Herbal Medicines in Management of Inflammatory Bowel Diseases: A Systematic Review of Animal and Human Studies

verfasst von: Roja Rahimi, Shilan Mozaffari, Mohammad Abdollahi

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Because of potential adverse events and lack of effectiveness of standard therapies, the use of complementary and alternative medicines (CAM), particularly of herbal therapies, for inflammatory bowel disease (IBD) is increasing. Results from the use of herbal therapies for managing IBD are promising, and no serious adverse events have been reported from them. Herbal therapies show their benefit in managing IBD by different mechanisms such as immune system regulation, antioxidant activity, inhibition of leukotriene B4, inhibition of nuclear factor-kappa B (NF-κB), and antiplatelet activity. In this paper, all reported herbal therapies established in animal IBD models or used for managing human IBD are systematically reviewed and their possible mechanisms of action discussed. Conducting clinical trials with high quality and validity (randomized, double blinded, controlled, on a large number of patients) to obtain more conclusive results about the use of herbal therapies in IBD is recommended.

Rezaie A, Parker RD, Abdollahi M (2007) Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52:2015–2021. doi:10.1007/s10620-006-9622-2 PubMedCrossRef

Trallori G, Palli D, Saieva C, Bardazzi G, Bonanomi AG, d’Albasio G et al (1996) A population-based study of inflammatory bowel disease in Florence over 15 years (1978–1992). Scand J Gastroenterol 31:892–899. doi:10.3109/00365529609051998 PubMedCrossRef

Rahimi R, Nikfar S, Larijani B, Abdollahi M (2005) A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 59:365–373. doi:10.1016/j.biopha.2005.07.002 PubMedCrossRef

Treasure J (2005) Herbal medicine and cancer: an introductory overview. Semin Oncol Nurs 21:177–183. doi:10.1016/j.soncn.2005.04.006 PubMedCrossRef

Stickel F, Schuppan D (2007) Herbal medicine in the treatment of liver diseases. Dig Liver Dis 39:293–304. doi:10.1016/j.dld.2006.11.004 PubMedCrossRef

Salari P, Rezaie A, Larijani B, Abdollahi M (2008) A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med Sci Monit 14:RA37–RA44PubMed

Langmead L, Rampton DS (2006) Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 23:341–349. doi:10.1111/j.1365-2036.2006.02761.x PubMedCrossRef

Bensoussan M, Jovenin N, Garcia B, Vandromme L, Jolly D, Bouché O et al (2006) Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol 30:14–23. doi:10.1016/S0399-8320(06)73072-X PubMed

Langhorst J, Anthonisen IB, Steder-Neukamm U, Lüdtke R, Spahn G, Michalsen A et al (2005) Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 11:287–295. doi:10.1097/01.MIB.0000160771.71328.6c PubMedCrossRef

10.

Hilsden RJ, Verhoef MJ, Best A, Pocobelli G (2003) Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol 98:1563–1568. doi:10.1111/j.1572-0241.2003.07519.x PubMedCrossRef

11.

Day AS, Whitten KE, Bohane TD (2004) Use of complementary and alternative medicines by children and adolescents with inflammatory bowel disease. J Paediatr Child Health 40:681–684. doi:10.1111/j.1440-1754.2004.00510.x PubMedCrossRef

12.

Kaplan M, Mutlu EA, Benson M, Fields JZ, Banan A, Keshavarzian A (2007) Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders. Complement Ther Med 15:207–216. doi:10.1016/j.ctim.2006.06.005 PubMedCrossRef

13.

Kucharzik T, Maaser C, Lügering A, Kagnoff M, Mayer L, Targan S et al (2006) Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 12:1068–1083. doi:10.1097/01.mib.0000235827.21778.d5 PubMedCrossRef

14.

Brown SJ, Mayer L (2007) The immune response in inflammatory bowel disease. Am J Gastroenterol 102:2058–2069. doi:10.1111/j.1572-0241.2007.01343.x PubMedCrossRef

15.

Scaldaferri F, Fiocchi C (2007) Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 8:171–178. doi:10.1111/j.1751-2980.2007.00310.x PubMedCrossRef

16.

Elsässer-Beile U, von Kleist S, Gerlach S, Gallati H, Mönting JS (1994) Cytokine production in whole blood cell cultures of patients with Crohn’s disease and ulcerative colitis. J Clin Lab Anal 8:447–451. doi:10.1002/jcla.1860080618 PubMedCrossRef

17.

Marano CW, Lewis SA, Garulacan AP, Soler LA, Mullin JM (1998) Tumor necrosis factor-α increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal epithelial cell line. J Membr Biol 161:263–274. doi:10.1007/s002329900333 PubMedCrossRef

18.

Rahimi R, Nikfar S, Abdollahi M (2007) Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 13:PI13–PI18PubMed

19.

Rahimi R, Nikfar S, Abdollahi M (2007) Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 61:75–80. doi:10.1016/j.biopha.2006.06.022 PubMedCrossRef

20.

Rezaie A, Taghavi Bayat B, Abdollahi M (2005) Biologic management of fistulizing Crohn’s disease. Int J Pharmacol 1:17–24

21.

Zhang M, Deng CS, Zheng JJ, Xia J (2006) Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 27:1071–1077. doi:10.1111/j.1745-7254.2006.00322.x PubMedCrossRef

22.

Jiang H, Deng CS, Zhang M, Xia J (2006) Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 12:3848–3853PubMed

23.

Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, Fang YX (2005) Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11:1747–1752PubMed

24.

Jian YT, Wang JD, Mai GF, Zhang YL, Lai ZS (2004) Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis. Di Yi Jun Yi Da Xue Xue Bao 24:1353–1358PubMed

25.

Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T et al (2002) Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123:1912–1922. doi:10.1053/gast.2002.37050 PubMedCrossRef

26.

Ren J, Tao Q, Wang X, Wang Z, Li J (2007) Efficacy of T2 in active Crohn’s disease: a prospective study report. Dig Dis Sci 52:1790–1797. doi:10.1007/s10620-007-9747-y PubMedCrossRef

27.

Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK (2007) Chios mastic treatment of patients with active Crohn’s disease. World J Gastroenterol 13:748–753. doi:10.3748/wjg.13.6031 PubMedCrossRef

28.

Wang X, Zhao L, Han T, Chen S, Wang J (2008) Protective effects of 2, 3, 5, 4′-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. Eur J Pharmacol 578:339–348. doi:10.1016/j.ejphar.2007.09.013 PubMedCrossRef

29.

Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G et al (2007) Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med 4:43–50. doi:10.1093/ecam/nel051 PubMedCrossRef

30.

Hausmann M, Obermeier F, Paper DH, Balan K, Dunger N, Menzel K et al (2007) In vivo treatment with the herbal phenylethanoid acetonide ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clin Exp Immunol 148:373–381PubMedCrossRef

31.

Deguchi Y, Andoh A, Inatomi O, Yagi Y, Bamba S, Araki Y et al (2007) Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. Dig Dis Sci 52:2993–2998. doi:10.1007/s10620-006-9138-9 PubMedCrossRef

32.

Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S, Motilva V et al (2007) Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7:333–342. doi:10.1016/j.intimp. 2006.11.006 PubMedCrossRef

33.

Ghafari H, Yasa N, Mohammadirad A, Dehghan G, Zamani MJ, Nikfar S et al (2006) Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum Exp Toxicol 25:325–332. doi:10.1191/0960327105ht626oa PubMedCrossRef

34.

Ghazanfari G, Minaie B, Yasa N, Nakhai L, Mohammadirad A, Nikfar S et al (2006) Biochemical and histopathological evidences for beneficial effects of Satureja Khuzestanica Jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 16:365–372. doi:10.1080/15376520600620125 CrossRefPubMed

35.

Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P et al (2006) Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 92642:2006

36.

Zhang M, Deng C, Zheng J, Xia J, Sheng D (2006) Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol 6:1233–1242. doi:10.1016/j.intimp. 2006.02.013 PubMedCrossRef

37.

Mustafa A, El-Medany A, Hagar HH, El-Medany G (2006) Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis. Pharmacol Res 53:324–330. doi:10.1016/j.phrs.2005.12.010 PubMedCrossRef

38.

Oh PS, Lim KT (2006) Plant originated glycoprotein has anti-oxidative and anti-inflammatory effects on dextran sulfate sodium-induced colitis in mouse. J Biomed Sci 13:549–560. doi:10.1007/s11373-006-9083-9 PubMedCrossRef

39.

Cheon JH, Kim JS, Kim JM, Kim N, Jung HC, Song IS (2006) Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm Bowel Dis 12:1152–1161. doi:10.1097/01.mib.0000235830.94057.c6 PubMedCrossRef

40.

Ukil A, Maity S, Das PK (2006) Protection from experimental colitis by theaflavin-3, 3′-digallate correlates with inhibition of IKK and NF-kappaB activation. Br J Pharmacol 149:121–131. doi:10.1038/sj.bjp. 0706847 PubMedCrossRef

41.

Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Müller S et al (2006) Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 290:G1131–G1137. doi:10.1152/ajpgi.00562.2005 PubMedCrossRef

42.

Ko JK, Cho CH (2005) The diverse actions of nicotine and different extracted fractions from tobacco smoke against hapten-induced colitis in rats. Toxicol Sci 87:285–295. doi:10.1093/toxsci/kfi238 PubMedCrossRef

43.

Kiela PR, Midura AJ, Kuscuoglu N, Jolad SD, Sólyom AM, Besselsen DG et al (2005) Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol 288:G798–G808. doi:10.1152/ajpgi.00433.2004 PubMedCrossRef

44.

Kim SW, Choi SC, Choi EY, Kim KS, Oh JM, Lee HJ et al (2004) Catalposide, a compound isolated from Catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice. Inflamm Bowel Dis 10:564–572. doi:10.1097/00054725-200409000-00010 PubMedCrossRef

45.

Murakami A, Hayashi R, Tanaka T, Kwon KH, Ohigashi H, Safitri R (2003) Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. Biochem Pharmacol 66:1253–1261. doi:10.1016/S0006-2952(03)00446-5 PubMedCrossRef

46.

Maity S, Ukil A, Karmakar S, Datta N, Chaudhuri T, Vedasiromoni JR et al (2003) Thearubigin, the major polyphenol of black tea, ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. Eur J Pharmacol 30(470):103–112. doi:10.1016/S0014-2999(03)01760-6 CrossRef

47.

Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK (2003) Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139:209–218. doi:10.1038/sj.bjp. 0705241 PubMedCrossRef

48.

Micallef MJ, Iwaki K, Ishihara T, Ushio S, Aga M, Kunikata T et al (2002) The natural plant product tryptanthrin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol 2:565–578. doi:10.1016/S1567-5769(01)00206-5 PubMedCrossRef

49.

Krieglstein CF, Anthoni C, Rijcken EJ, Laukötter M, Spiegel HU, Boden SE et al (2001) Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16:88–95. doi:10.1007/s003840100292 PubMedCrossRef

50.

Omer B, Krebs S, Omer H, Noor TO (2007) Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn’s disease: a double-blind placebo-controlled study. Phytomedicine 14:87–95. doi:10.1016/j.phymed.2007.01.001 PubMedCrossRef

51.

Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A et al (2004) Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 19:739–747. doi:10.1111/j.1365-2036.2004.01902.x PubMedCrossRef

52.

Dong WG, Liu SP, Zhu HH, Luo HS, Yu JP (2004) Abnormal function of platelets and role of Angelica sinensis in patients with ulcerative colitis. World J Gastroenterol 10:606–609PubMed

53.

Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E (2002) Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37:444–449. doi:10.1080/003655202317316088 PubMedCrossRef

54.

Gupta I, Parihar A, Malhotra P, Gupta S, Lüdtke R, Safayhi H et al (2001) Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67:391–395. doi:10.1055/s-2001-15802 PubMedCrossRef

55.

Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R (2001) Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 39(1):11–17. doi:10.1055/s-2001-10708 PubMedCrossRef

56.

Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A et al (1999) Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish group for the study of Crohn’s disease and ulcerative colitis (GETECCU. Am J Gastroenterol 94:427–433PubMed

57.

Gupta I, Parihar A, Malhotra P, Singh GB, Lüdtke R, Safayhi H et al (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2(1):37–43PubMed

58.

Greenfield SM, Green AT, Teare JP, Jenkins AP, Punchard NA, Ainley CC et al (1993) A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 7:159–166PubMed

59.

Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B et al (2006) Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in Crohn’s disease patients. Ann N Y Acad Sci 1091:110–122. doi:10.1196/annals.1378.060 PubMedCrossRef

60.

Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M (2004) Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 49:1752–1757. doi:10.1007/s10620-004-9564-5 PubMedCrossRef

61.

Liu L, Wang ZP, Xu CT, Pan BR, Mei QB, Long Y et al (2003) Effects of Rheum tanguticum polysaccharide on TNBS-induced colitis and CD4+T cells in rats. World J Gastroenterol 9:2284–2288PubMed

62.

Liu L, Mei QB, Zhou SY, Han FH, Long Y, Liu JY et al (2003) Effects of tanguticum maxim polysaccharide on ulcerative colitis induced by TNBS in rats. Zhongguo Zhong Yao Za Zhi 28:246–249PubMed

63.

Ford-Hutchinson AW, Evans JF (1986) Leukotriene B₄: biological properties and regulation of biosynthesis. In: Piper PJ (ed) Leukotrienes: their biological significance. Raven Press, New York, pp 141–150

64.

Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86:453–460PubMed

65.

Kruis W (2004) Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 20:75–78. doi:10.1111/j.1365-2036.2004.02051.x PubMedCrossRef

66.

Sartor RB (2003) Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol. 19:358–365PubMedCrossRef

67.

Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M et al (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54. doi:10.1053/gast.2002.30294 PubMedCrossRef

68.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M (2006) A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther 28:1983–1988. doi:10.1016/j.clinthera.2006.12.012 PubMedCrossRef

69.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M (2007) A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 52:2920–2925. doi:10.1007/s10620-007-9760-1 PubMedCrossRef

70.

Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82:434–448. doi:10.1007/s00109-004-0555-y PubMedCrossRef

71.

Egan LJ, Toruner M (2006) NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach. Ann N Y Acad Sci 1072:114–122. doi:10.1196/annals.1326.009 PubMedCrossRef

72.

Schreiber S, Nikolaus S, Hampe J (1998) Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42:477–484PubMedCrossRef

73.

Andresen L, Jørgensen VL, Perner A, Hansen A, Eugen-Olsen J, Rask-Madsen J (2005) Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54:503–509. doi:10.1136/gut.2003.034165 PubMedCrossRef

74.

Yamamoto Y, Gaynor RB (2004) IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 29:72–79. doi:10.1016/j.tibs.2003.12.003 PubMedCrossRef

75.

Martín MC, Martinez A, Mendoza JL, Taxonera C, Díaz-Rubio M, Fernández-Arquero M et al (2007) Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility. Immunogenetics 59:833–837. doi:10.1007/s00251-007-0255-1 PubMedCrossRef

76.

Lundberg JO, Hellström PM, Lundberg JM, Alving K (1994) Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 344:1673–1674. doi:10.1016/S0140-6736(94)90460-X PubMedCrossRef

77.

Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A et al (2007) Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 1095:305–314. doi:10.1196/annals.1397.034 PubMedCrossRef

78.

Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ (2002) Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97:910–914. doi:10.1111/j.1572-0241.2002.05608.x PubMedCrossRef

79.

Miedany Y, Youssef S, Ahmed I, El Gaafary M (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101:311–317. doi:10.1111/j.1572-0241.2006.00384.x PubMedCrossRef

80.

Talstad I, Rootwelt K, Gjone E (1973) Thrombocytosis in ulcerative colitis and Crohn’s disease. Scand J Gastroenterol 8:135–138PubMed

81.

Lake AM, Stauffer JQ, Stuart MJ (1978) Hemostatic alterations in inflammatory bowel disease: response to therapy. Am J Dig Dis 23:897–902. doi:10.1007/BF01072463 PubMedCrossRef

82.

Collins CE, Rampton DS (1997) Review article: platelets in inflammatory bowel disease—pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 11:237–247. doi:10.1046/j.1365-2036.1997.153328000.x PubMedCrossRef

83.

Pitchford SC (2007) Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol 152:987–1002. doi:10.1038/sj.bjp. 0707364 PubMedCrossRef

Titel: On the Use of Herbal Medicines in Management of Inflammatory Bowel Diseases: A Systematic Review of Animal and Human Studies
verfasst von: Roja Rahimi
Shilan Mozaffari
Mohammad Abdollahi
Publikationsdatum: 01.03.2009
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 3/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0368-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

MCM2 and MCM5 as Prognostic Markers in Colon Cancer: A Worthwhile Approach

Clinical Significance of Interleukin-6 (Il-6) Gene Polymorphism and Il-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis

Activation of Interleukin-6/STAT3 in Rat Cholangiocyte Proliferation Induced by Lipopolysaccharide

The Role of Gastroesophageal Reflux in Exercise-Triggered Asthma: A Randomized Controlled Trial

The Effects of Capsaicin on Gastrin Secretion in Isolated Human Antral Glands: Before and After Ingestion of Red Chilli